Table 1 Demographic characteristics of total sample

From: Piccolo genotype modulates neural correlates of emotion processing but not executive functioning

Characteristics

Tower of London planning task

Emotional face paradigm

  

Genotype

    

Genotype

   
 

Total

PCLO+

PCLO−

χ 2

P-value

Total

PCLO+

PCLO−

χ 2

P-value

Number of subjects

159

110

49

  

126

90

36

  

Gender (%female)

64.1

64.5

63.3

0.024

>0.05

61.9

61.1

63.8

0.08

>0.05

Age (mean years ±s.d.)

38.17 (10.7)

37.9 (10.2)

38.8 (11.9)

 

>0.05

38.1 (10.3)

38.0 (10.2)

38.4 (10.7)

 

>0.05

Education (mean years ±s.d.)

12.5 (3.1)

12.8 (3.3)

11.9 (2.8)

 

>0.05

12.6 (3.1)

12.8 (3.2)

12.1 (2.8)

 

>0.05

Scan center (A/L/G)

42/62/55

28/46/36

14/16/19

1.21

>0.05

24/54/48

19/40/31

5/14/17

1.99

>0.05

Diagnosis (MDD/HC)

118/41

84/26

35/15

0.86

>0.05

96/30

69/21

27/9

0.04

>0.05

IDS (mean score ±s.d.)

18.90 (13.5)

20.06 (13.2)

16.27 (14.0)

 

>0.05

19.46 (13.9)

20.05 (13.6)

17.91 (14.8)

 

>0.05

MADRS (mean score ±s.d.)

11.89 (10.4)

13.01 (10.3)

9.39 (10.1)

 

=0.042

12.78 (10.4)

13.53 (10.3)

10.80 (10.4)

 

>0.05

Duration of SSRI use (months ±s.d.)

22.91 (37.6)

27.77 (38.8)

18.80 (36.5)

 

>0.05

23 (36.9)

24.75 (37.7)

18.8 (36.5)

 

>0.05

SSRI use (no/yes)

119/40

82/28

37/12

 

>0.05

92/34

67/24

25/10

 

>0.05

  1. Abbreviations: HC, healthy controls; IDS, inventory of depressive symptomatology; MADRS, Montgomery–Åsberg Depression Rating Scale; MDD, major depressive disorder; PCLO, piccolo; SSRI, selective serotonin reuptake inhibitor.